Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine headlines to help you catch up and stay informed. It was a busy week with lots of news, have a look and see you next week for another update.
Compass Pathways Launches New Phase 2 Trial for Anorexia
Taking place at prestigious sites like King’s College London and Columbia University, the trial is “a multi-centre, double-blind randomized controlled phase II clinical trial investigating the efficacy of COMP360 psilocybin, administered with psychological support, in people with anorexia nervosa.”
Dr Guy Goodwin, Chief Medical Officer, COMPASS Pathways: “There are no approved pharmacological treatment options for people living with anorexia nervosa, and we are determined to change this. We are conducting this rigorous clinical trial to understand whether COMP360 psilocybin, with psychological support, could help people living with anorexia nervosa who urgently need new options.”
Small Pharma Granted U.S. Patent for Injectable DMT
Small Pharma is granted an important patent for their DMT programs, a key U.S. patent protection on injectable delivery of DMT in lead programs SPL026 and SPL028. And the investment community has noticed the news, as Roth Capital reiterates their Buy rating and bullish price target.
HAVN Life Announces a 30:1 Consolidation of its Common Shares
The decision to was taken by the Board of Directors after carefully considering a number of factors, including the significant decline in the company’s share price, the significant decline in the market values of many other companies operating in the psychedelic sector, and the related challenges companies in the sector are facing in completing financings, particularly equity financings. The company says it will provide greater flexibility in attracting potential financing.
Canadian Government Issues First Ever Grant to Study Psilocybin
The Canadian government has given its first-ever grant to study if psilocybin can be used to treat depression without the psychedelic effects. The grant was given to Toronto’s Centre for Addiction and Mental Health (CAMH) for a new clinical trial entitled “A proof-of-concept randomized controlled trial to show that the antidepressant effects of psilocybin do not require psychedelic effects.”
Project Solace: The World’s Largest Psilocybin Access and Data Project
The world’s largest medical psilocybin access and data project set to launch, led by Canadian non-profit TheraPsil. Real-world data aims to inform development of regulated psilocybin therapy.
Through Project Solace, TheraPsil will support prescribing healthcare practitioners in Canada to feel confident and capable to request psilocybin-based medical products on behalf of their patients through the SAP. As part of ensuring patient safety and treatment efficacy, TheraPsil will also identify and connect prescribing healthcare professionals with trained treatment therapy teams across Canada that will support patients in medical need through the facilitation of psilocybin-assisted psychotherapy.
Nonprofit B.More Submits Phase 2b Trial for Alcohol Use to the FDA
Nonprofit “B.More” has submitted an IND application to the FDA to begin a Phase 2b trial to determine the efficacy and safety of synthetic psilocybin (SYNP-101) in treating alcohol use disorder (AUD). The trial expects to be initiated in early 2023.
According to Carey Turnbull, co-founder and CEO of B.More, “B.More’s psilocybin AUD program IND application is a major step forward in our mission to develop psychedelic medicines for individual struggling with alcohol use disorder. Our Phase 2b trial builds on the impressive work led by Dr. Bogenschutz and will provide vital data to further advance our drug development program.”
